Form 4: QuidelOrtho CTO Reports Stock Transaction
Insider Transaction (Form 4)
Jonathan Philip Siegrist, EVP of R&D & CTO of QuidelOrtho Corp, reported multiple transactions in common stock on October 15, 2026.
Summary
- Option exercise/conversion: acquired 18,657 Common Stock on October 15, 2026; holds 32,076 after (Direct).
- Tax/exercise-price withholding: disposed of 6,695 Common Stock at $13.91 ($93,127) on October 15, 2026; holds 25,381 after (Direct).
- Option exercise/conversion: disposed of 18,657 Restricted Stock Units on October 15, 2026; holds 18,657 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jonathan Philip Siegrist — Officer (EVP of R&D & CTO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-15 | Option exercise/conversion | Common Stock | 18,657 | — | — | 32,076 |
| 2026-10-15 | Tax/exercise-price withholding | Common Stock | 6,695 | $14 | $93.1K | 25,381 |
| 2026-10-15 | Option exercise/conversion | Restricted Stock Units | 18,657 | — | — | 18,657 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-15 | Option exercise/conversion (18,657 shares) |
| 2026-10-15 | Tax/exercise-price withholding (6,695 shares) |
| 2026-10-15 | Option exercise/conversion (18,657 shares) |
Keywords
insider transaction, Form 4, QDEL, QuidelOrtho Corp, neutral, Jonathan Philip Siegrist
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.